Article Sidebar
Published:
Apr 14, 2024DOI:
10.4314/tjpr.v23i3.7Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Protective effect of remimazolam on neuronal cells from OGD/R induced damage: An in vitro study
Abstract
Purpose: To investigate the effect of remimazolam (Re) on oxygen glucose deprivation/reoxygenation (OGD/R) model, and to elucidate the mechanism of action.
Methods: The neuron cells were treated with OGD/R. MTT assays were performed to confirm The effect of Re on cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, while flow cytometry (FCM) assay was conducted to determine the apoptosis of OGD/R cells. Immunostaining assay and enzyme-linked immunosorbent assay (ELISA) were used to evaluate the effects of Re on mitochondria damage, while immunoblot assay was used unravel its mechanism of action.
Results: Remimazolam (Re) significantly enhanced OGD/R-induced neuronal survival (p < 0.05). In addition, it significantly inhibited OGD/R-induced neuronal apoptosis, and OGD/R-induced neuron mitochondrial damage. Furthermore, it suppressed MAPK pathway in OGD/R-induced neuron, thus protecting the neuronal cells from OGD/R-induced damage (p < 0.05).
Conclusion: Remimazolam protects neuronal cells from OGD/R-induced damage by mediating MAPK pathway. Therefore, it is a potential drug for the management of Ischemia-reperfusion injury (IRI). However, in vivo studies are required to buttress this.
